EUVIMEDOpdag EUVIMED
CrossrefInfokort

A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents

Rochelle Woodland, Adi Suwandi, Awgichew Behaile Teklemariam, Nidhish Francis, Li Li, Kenneth A. Chinkwo, Jonathan B. Baell, David J. Leaver

ChemMedChem · 2026-10-28 · 21 (20)

DOI: 10.1002/cmdc.70534 ↗
AbstractBibliografiske oplysninger

Abstract

The development of lysine acetyltransferase (KAT) inhibitors as anticancer agents has progressed rapidly from initial tool compounds to numerous molecules entering clinical trials. The most clinically advanced KAT6A inhibitor, prifetrastat (PF‐07248144), entered Phase III clinical trials in 2025. The discovery of prifetrastat is an excellent example of instrumental contributions made by Australian biomedical and medicinal chemistry researchers to the creation of innovative and cutting‐edge anticancer therapeutics. Within this perspective we summarize KAT6A structural biology and structure–activity relationships (SAR) for acylsulfonylhydrazides, [1,2,4]thiadiazines and benzisoxazole sulfonamide inhibitors in addition to providing updates on KAT6A inhibitors that have already entered into clinical trials. Key clinical challenges and opportunities facing the field are discussed herein.

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.

Se priser →